# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frédéric Chopin (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI020-SYN-TD
- Date: 1838-03-17
- Fictional facility: St. Posthumous Health Center
- Fictional author: Matthias Lindqvist, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- He has coughed for about three months, now with streaks of blood, sweats at night, and has lost weight; he wants to know what is wrong **S**
- He teaches piano at home and performs; he wants to know when he can teach again and whether his students are at risk **S**
- He is afraid his students and neighbors will shun him if they learn he may have tuberculosis **S**

## Your goals

- Complete all 119 doses within five months by video-observed therapy. Target: 1838-07-21. Recorded outcome: All 119 doses completed in 17 weeks: 56 in the intensive phase and 63 in the continuation phase, with none missed. **S**
- Sputum culture negative at two months. Target: 1838-07-21. Recorded outcome: The two-month culture showed no growth, as did the cultures from the third week. **S**
- Return to teaching once the health department confirms he is no longer infectious. Target: 1838-04-07. Recorded outcome: Released from isolation after three negative smears and more than two weeks of treatment; teaching again from the third week. **S**
- Weight back to at least 55 kg by the end of treatment. Target: 1838-07-21. Recorded outcome: 55.0 kg at the end of treatment, from 48.5 kg at diagnosis. **S**
- PHQ-9 below 5 by the end of treatment. Target: 1838-07-21. Recorded outcome: PHQ-9 3 at the end of treatment, from 7 at diagnosis. **S**

## What we agreed to do

- Infectious diseases consultation to confirm the diagnosis, choose between the six-month and four-month regimens, plan monitoring and his return to teaching, and address cystic fibrosis and alpha-1 antitrypsin deficiency as explanations for his lifelong chest illness. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022) **S**
- Diagnosis: three sputum samples at least eight hours apart, one early in the morning, for acid-fast smear, nucleic acid amplification with rifampin resistance, culture, molecular testing for isoniazid and fluoroquinolone resistance, and phenotypic susceptibility; an interferon-gamma release assay; HIV, hepatitis B, and hepatitis C tests; and baseline blood count, liver and kidney tests, potassium, calcium, and magnesium. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022) **S**
- Infection control and public health: home airborne isolation with no students or visitors and a surgical mask around others; same-day report of suspected tuberculosis to the health department; a contact investigation of his students, friends, and other close contacts led by the health department. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005) **S**
- Nutrition: two dietitian visits in the first month, three meals and three energy-dense snacks a day, two oral nutrition supplement drinks a day, and weight at every visit. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012) **S**
- Support: plain information about how tuberculosis spreads, how quickly treatment makes him non-infectious, and that it is curable; help with what to tell his students; PHQ-9 at diagnosis, at two months, and at the end of treatment. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Depression and Suicide Risk in Adults: Screening (2023) **S**
- Treatment: the four-month regimen of rifapentine 1200 mg, moxifloxacin 400 mg, isoniazid 300 mg, and pyrazinamide 1000 mg daily with food for eight weeks, then rifapentine, moxifloxacin, and isoniazid for nine weeks, with pyridoxine, by video-observed therapy seven days a week; complete when 119 doses are taken within five months. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022); Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (2025) **S**
- Monitoring: symptoms, weight, adverse effects (liver, tendons, nerves) and observed doses at every visit; liver tests at two to three weeks and for symptoms; sputum smears in the third week for release, then monthly culture until two are negative, including the two-month culture; phenotypic susceptibility including moxifloxacin; PHQ-9 at two months and at the end. Guideline: Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006) **S**
- Sweat chloride test and serum alpha-1 antitrypsin level once he is out of isolation, to address cystic fibrosis and alpha-1 antitrypsin deficiency as the proposed alternatives. Guideline: Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation (2017); American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency (2003) **S**

## Follow-up

- 1838-03-17: Three months of cough, two weeks of blood-streaked sputum, night sweats, and weight loss: chest X-ray and CT, sputum samples, blood tests, home airborne isolation, and a report of suspected tuberculosis to the health department **S**
- 1838-03-20: Results visit: pulmonary tuberculosis confirmed; infectious diseases consultation and the start of the four-month rifapentine-moxifloxacin regimen by video-observed therapy **S**
- 1838-04-07: Two-and-a-half-week review: release from isolation, return to teaching, liver tests, and tests for cystic fibrosis and alpha-1 antitrypsin deficiency **S**
- 1838-05-15: End of the eight-week intensive phase: susceptibility results, the two-month sputum culture, and the start of the continuation phase **S**
- 1838-07-21: End-of-treatment review after 119 doses **S**
- 1838-09-15: Adult preventive visit **S**

This teaching document does not replace care from a qualified clinician.
